SELECTION SUMMARY
도입 판단 요약
View quarterly trends in Risky Prescribing Measures, including: o Number/Rate of Individuals Seeing 5+ Prescribers and 5+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 4+ Prescribers and 4+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 3+ Prescribers and 3+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals with an Average Daily MME >50, >90 or >120: Average Daily MME is calculated as the sum of the total MME on each day in a time period based on all prescriptions an individual has filled divided by the number of days in the prescription(s). Measures include the number and rate of individuals prescribed greater than 50 MME per day, greater than 90 MME per day, or greater than 120 MME per day and is based on the patient’s county of residence. o Number/Rate of Individuals with Overlapping Opioid/Benzodiazepine Prescriptions: Number of individuals receiving overlapping opioid and benzodiazepine prescriptions during a given quarter. This measure is based on the patients’ county of residence. o Number/Rate of Individuals with > 30 Days of Overlapping Opioid/Benzodiazepine Prescriptions: Number and rate of individuals receiving overlapping opioid and benzodiazepine prescriptions for 30 days or more during a given quarter using state/county populations as denominators. This measure is based on the patients’ county of residence. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx
이 제품의 적합 용도와 제한 조건은 아직 검수하지 않았습니다. 태그와 카테고리는 찾아가는 길이지 적합성 보증이 아닙니다.